MicroRNA-based Therapy in Animal Models of Selected Gastrointestinal Cancers

Gastrointestinal cancer accounts for the 20 most frequent cancer diseases worldwide and there is a constant urge to bring new therapeutics with new mechanism of action into the clinical practice. Quantity of in vitro and in vivo evidences indicate, that exogenous change in pathologically imbalanced...

Full description

Bibliographic Details
Main Authors: Jana Merhautova, Regina Demlova, Ondrej Slaby
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-09-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00329/full
id doaj-0d6cc8ccbbfe4e08a98b7e5163b31175
record_format Article
spelling doaj-0d6cc8ccbbfe4e08a98b7e5163b311752020-11-24T23:44:20ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122016-09-01710.3389/fphar.2016.00329216844MicroRNA-based Therapy in Animal Models of Selected Gastrointestinal CancersJana Merhautova0Regina Demlova1Regina Demlova2Ondrej Slaby3Ondrej Slaby4Masaryk UniversityMasaryk UniversityMasaryk Memorial Cancer InstituteMasaryk UniversityMasaryk Memorial Cancer InstituteGastrointestinal cancer accounts for the 20 most frequent cancer diseases worldwide and there is a constant urge to bring new therapeutics with new mechanism of action into the clinical practice. Quantity of in vitro and in vivo evidences indicate, that exogenous change in pathologically imbalanced microRNAs (miRNAs) is capable of transforming the cancer cell phenotype. This review analyzed preclinical miRNA-based therapy attempts in animal models of gastric, pancreatic, gallbladder, and colorectal cancer. From more than 400 original articles, 26 was found to assess the effect of miRNA mimics, precursors, expression vectors, or inhibitors administered locally or systemically being an approach with relatively high translational potential. We have focused on mapping available information on animal model used (animal strain, cell line, xenograft method), pharmacological aspects (oligonucleotide chemistry, delivery system, posology, route of administration) and toxicology assessments. We also summarize findings in the field pharmacokinetics and toxicity of miRNA-based therapy.□http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00329/fullMicemicroRNAcolorectal canceranimal modelPancreatic Cancergastric cancer
collection DOAJ
language English
format Article
sources DOAJ
author Jana Merhautova
Regina Demlova
Regina Demlova
Ondrej Slaby
Ondrej Slaby
spellingShingle Jana Merhautova
Regina Demlova
Regina Demlova
Ondrej Slaby
Ondrej Slaby
MicroRNA-based Therapy in Animal Models of Selected Gastrointestinal Cancers
Frontiers in Pharmacology
Mice
microRNA
colorectal cancer
animal model
Pancreatic Cancer
gastric cancer
author_facet Jana Merhautova
Regina Demlova
Regina Demlova
Ondrej Slaby
Ondrej Slaby
author_sort Jana Merhautova
title MicroRNA-based Therapy in Animal Models of Selected Gastrointestinal Cancers
title_short MicroRNA-based Therapy in Animal Models of Selected Gastrointestinal Cancers
title_full MicroRNA-based Therapy in Animal Models of Selected Gastrointestinal Cancers
title_fullStr MicroRNA-based Therapy in Animal Models of Selected Gastrointestinal Cancers
title_full_unstemmed MicroRNA-based Therapy in Animal Models of Selected Gastrointestinal Cancers
title_sort microrna-based therapy in animal models of selected gastrointestinal cancers
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2016-09-01
description Gastrointestinal cancer accounts for the 20 most frequent cancer diseases worldwide and there is a constant urge to bring new therapeutics with new mechanism of action into the clinical practice. Quantity of in vitro and in vivo evidences indicate, that exogenous change in pathologically imbalanced microRNAs (miRNAs) is capable of transforming the cancer cell phenotype. This review analyzed preclinical miRNA-based therapy attempts in animal models of gastric, pancreatic, gallbladder, and colorectal cancer. From more than 400 original articles, 26 was found to assess the effect of miRNA mimics, precursors, expression vectors, or inhibitors administered locally or systemically being an approach with relatively high translational potential. We have focused on mapping available information on animal model used (animal strain, cell line, xenograft method), pharmacological aspects (oligonucleotide chemistry, delivery system, posology, route of administration) and toxicology assessments. We also summarize findings in the field pharmacokinetics and toxicity of miRNA-based therapy.□
topic Mice
microRNA
colorectal cancer
animal model
Pancreatic Cancer
gastric cancer
url http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00329/full
work_keys_str_mv AT janamerhautova micrornabasedtherapyinanimalmodelsofselectedgastrointestinalcancers
AT reginademlova micrornabasedtherapyinanimalmodelsofselectedgastrointestinalcancers
AT reginademlova micrornabasedtherapyinanimalmodelsofselectedgastrointestinalcancers
AT ondrejslaby micrornabasedtherapyinanimalmodelsofselectedgastrointestinalcancers
AT ondrejslaby micrornabasedtherapyinanimalmodelsofselectedgastrointestinalcancers
_version_ 1725499050142203904